Current concepts in the pharmacotherapy of acute psychosis

CNS Drugs

Volumn 9, Issue 3, 1998, Pages 191-202

  Remington, Gary J ^a   Bezchlibnyk Butler, Kalyna ^a  

^a CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMOBARBITAL; BARBITURIC ACID DERIVATIVE; BENZODIAZEPINE DERIVATIVE; CHLORPROMAZINE; CLOZAPINE; DIAZEPAM; DROPERIDOL; HALOPERIDOL; LORAZEPAM; MIDAZOLAM; NEUROLEPTIC AGENT; OLANZAPINE; PARALDEHYDE; RISPERIDONE; SERTINDOLE; ZUCLOPENTHIXOL ACETATE;

ACUTE PSYCHOSIS; ALGORITHM; CARDIOVASCULAR DISEASE; CENTRAL NERVOUS SYSTEM DISEASE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG FORMULATION; DRUG HALF LIFE; ELECTROCONVULSIVE THERAPY; EXTRAPYRAMIDAL SYMPTOM; HUMAN; INTRAMUSCULAR DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; LONG TERM CARE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RESPIRATION DEPRESSION; REVIEW; SAFETY; SCHIZOPHRENIA; SEDATION; SYMPTOMATOLOGY;

EID: 0031969659     PISSN: 11727047     EISSN: None     Source Type: Journal    
DOI: 10.2165/00023210-199809030-00003     Document Type: Review

References (78)

1. Expert Consensus Committee. Treatment of schizophrenia. III. General treatment issues. J Clin Psychiatry 1996; 57 Suppl. 12B: 22-7
2. Johnstone EC, Crow TJ, Johnson AL, et al. The Northwick Park study of first episodes of schizophrenia. I. Br J Psychiatry 1986; 48: 115-20
3. Johnstone EC, Macmillan JF, Crow TJ. The occurrence of organic disease of possible or probable actiological significance in a population of 268 cases of first episode schizophrenia. Psychol Med 1987; 17: 371-9
4. Battaglia J, Spector IC. Utility of the CAT scan in a first psychotic episode. Gen Hosp Psychiatry 1988; 10: 398-401
5. Adams M, Kutcher S, Antoniw E, et al. Diagnostic utility of endocrine and neuroimaging screening tests in first-onset adolescent psychosis. J Am Acad Child Adolesc Psychiatry 1996; 35: 67-73
6. Munk-Jorgensen P. The schizophrenia diagnosis in Denmark: a register-based investigation. Acta Psychiatr Scand 1985; 72: 266-73
7. Lenz G, Simhandl C, Thau K. Temporal stability and predictive validity of diagnostic criteria for schizophrenia [abstract]. Schizophr Res 1992; 6: 170
8. Fennig S, Kovasznay B, Rich C, et al. Six-month stability of psychiatric diagnoses in first-admission patients with psychoses. Am J Psychiatry 1994; 151: 1200-8
9. Wilson WH. Reassessment of state hospital patients diagnosed with schizophrenia. J Neuropsychiatry Clin Neurosci 1989; 1: 394-7
10. Smith GN, MacEwan GW, Aneill RJ, et al. Diagnostic confusion in treatment-refractory psychotic patients. J Clin Psychiatry 1982; 53: 197-200
11. Honer WG, Smith GN, MacEwan GW, et al. Diagnostic reassessment and treatment response in schizophrenia. J Clin Psychiatry 1994; 55: 528-32
12. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. Washington, DC: American Psychiatric Association, 1994
13. Baldessarini RJ, Cohen BM, Teicher MH. Significance of neuroleptic dose and plasma level in the pharmacological treatment of psychoses. Arch Gen Psychiatry 1988; 45: 79-91
14. Wyatt RJ. Risks of withdrawing antipsychotic medications. Arch Gen Psychiatry 1995; 52: 205-8
15. Kirkpatrik B, Buchannan RW, Waltrip II RW, et al. Diazepam treatment of early symptoms of schizophrenic relapse. J Nerv Ment Dis 1989; 177: 52-3
16. Wolkowitz OM, Pickar D. Benzodiazepines in the treatment of schizophrenia: a review and reappraisal. Am J Psychiatry 1991; 148: 714-26
17. Coryell W. Psychotic depression. J Clin Psychiatry 1996; 56 Suppl. 3: 27-31
18. Easton MS, Janicak PG. The use of benzodiazepines in psychotic disorders: a review of the literature. Psychiatr Ann 1990; 20: 535-44
19. Kane JM. The current status of neuroleptic therapy. J Clin Psychiatry 1989; 50: 322-8
20. Settle Jr EC, Ayd Jr FJ. Haloperidol: a quarter century of experience. J Clin Psychiatry 1983; 44: 440-8
21. Amdisen A, Aes-Jorgensen T, Thomsen NJ, et al. Serum concentrations and clinical effect of zuclopenthixol in acutely disturbed, psychotic patients treated with zuclopenthixol acetate in Viscoleo. Psychopharmacology 1986; 90: 412-6
22. Turns DM, Pary R, Tobias CR, et al. Depot neuroleptics for acutely psychotic patients [letter]. Am J Psychiatry 1987; 144: 1099
23. Remington G, Beschlibnyk-Butler K. Management of acute antipsychotic-induced extrapyramidal syndromes. CNS Drugs 1996; 5 Suppl. 1: 21-35
24. Salzman C, Green AI, Rodriguez-Villa F, et al. Benzodiazepines combined with neuroleptics for management of severe disruptive behavior. Psychosomatics 1986; 1 Suppl.: 17-21
25. Tuason VB. A comparison of parenteral loxapine and haloperidol in hostile and aggressive acutely schizophrenic patients. J Clin Psychiatry 1986; 46: 126-9
26. Baastrup PC, Alhfors UG, Bjerkenstedt L, et al. A controlled Nordic multicentre study of zuclopenthixol acetate in oil solution, haloperidol and zuclopenthixol in the treatment of acute psychosis. Acta Psychiatr Scand 1993; 87: 48-58
27. Curry SH. Commentary: the strategy and value of neuroleptic drug monitoring. J Clin Psychopharmacol 1985; 5: 263-7
28. Weiden P, Aquila R, Standard J. Atypical antipsychotic drugs and long-term outcome in schizophrenia. J Clin Psychiatry 1996; 57 Suppl. 11: 53-60
29. Remington GJ, Addington D, Collins E, et al. Clozapine: current status and role in the pharmacotherapy of schizophrenia. Can J Psychiatry 1996; 41: 161-6
30. Gardos G. Are antipsychotics interchangeable? J Nerv Ment Dis 1974; 159: 343-8
31. Hebenstreit GF. Clinical experience with zuclopenthixol acetate and co-injection of zuclopenthixol acetate and zuclopenthixol decanoate. In: Stefanis CN, Soldatas CR, Rabavilas AD, editors. Psychiatry: a world perspective. Vol. 3. Amsterdam: Elsevier Science Publishers B.V. (Biomedical Division), 1990: 196-201
32. Peralta P, Cuesta MJ, de Leon J. An empirical analysis of latent structures underlying schizophrenic symptoms: a four-syndrome model. Biol Psychiatry 1995; 35: 726-36
33. Gerlach J, Peacock L. New antipsychotics: the present status. Int Clin Psychopharmacol 1995; 10 Suppl. 3: 39-48
34. 4. Neuropsychopharmacology 1992; 7: 261-84
35. Baldessarini RJ, Katz B, Cotton P. Dissimilar dosing with high-potency and low-potency neuroleptics. Am J Psychiatry 1984; 141: 748-52
36. Donlon PT, Hopkin J, Tupin JP. Overview and safety of the rapid neuroleptization method with injectable haloperidol. Am J Psychiatry 1979; 136: 273-8
37. 2-dopamine receptor occupancy in relation to antipsychotic drug effects: a double-blind PET study of schizophrenic patients. Biol Psychiatry 1993; 33: 227-35
38. 2 receptor occupancy with low-dose haloperidol treatment: a PET study. Am J Psychiatry 1996; 153: 948-50
39. Remington GJ, Prendergast P, Bezchlibnyk-Butler KZ. Neuroleptic dosing in chronic schizophrenia: a 10-year follow-up. Can J Psychiatry 1997; 42: 53-7
40. Kane J. Psychopharmacologic treatment issues. Psychiatr Med 1990; 8: 111-24
41. Perry JC, Jacobs D. Overview: clinical applications of the amytal interview in psychiatric emergency settings. Am J Psychiatry 1982; 139: 552-9
42. Steiner W. The use of sodium amytal in psychogenic psychosis. Can J Psychiatry 1991; 36: 54-6
43. Mason AS, Granacher RP, editors. Clinical handbook of antipsychotic drug therapy. New York: Brunner/Mazel, 1980
44. Wyant M, Diamond BI, O'Neal E, et al. The use of midazolam in acutely agitated psychiatric patients. Psychopharmacol Bull 1990; 26: 126-9
45. Dubin WR, Weiss KJ, Dorin JM. Management of behavioral emergencies. Drug Ther Bull 1991; 29: 62-4
46. Dubin WR, Weiss KJ, Dorin JM. Pharmacotherapy of psychiatric emergencies. J Clin Psychopharmacol 1986; 6: 210-22
47. DiPalma JR, editor. Drill's pharmacology in medicine. 4th ed. New York: McGraw-Hill, 1971
48. Kittel J. Paraldehyde toxicity. Hosp Pharm 1973; 8: 263-5
49. Pilowsky LS, Ring H, Shine PJ, et al. Rapid tranquillisation: a survey of emergency prescribing in a general psychiatric hospital. Br J Psychiatry 1992; 160: 831-5
50. Resnick M, Burton BT. Droperidol vs haloperidol in the initial management of acutely agitated patients. J Clin Psychiatry 1984; 45: 298-9
51. van Leeuwen AMH, Molders J, Sterkmans P, et al. Droperidol in acutely agitated patients. J Nerv Ment Dis 1977; 154: 280-3
52. Granacher RP, Ruth DD. Droperidol in acute agitation. Curr Ther Res 1979; 25: 361-5
53. Szuba MP, Bergman KS, Baxter Jr LR, et al. Safety and efficacy of high-dose droperidol in agitated patients. J Clin Psychopharmacol 1992; 12: 144-5
54. Hooper JF, Minter G. Droperidol in the management of psychiatric emergencies. J Clin Psychopharmacol 1983; 3: 262-3
55. Ayd Jr F. Parenteral (IM/IV) droperidol for acutely disturbed behavior in psychotic and nonpsychotic individuals. Int Drug Ther Newsl 1980; 15: 3-16
56. Neff KE, Denney D, Blackly PH. Control of severe agitation with droperidol. Dis Nerv Syst 1972; 33: 594-7
57. Modell JG, Lenox RH, Weiner S. In-patient clinical trial of lorazepam for the management of manic agitation. J Clin Psychopharmacol 1985; 5: 109-13
58. Salzman C, Solomon D, Miyawaki E, et al. Parenteral lorazepam versus parenteral haloperidol for the control of psychotic disruptive behavior. J Clin Psychiatry 1991; 52: 177-80
59. Ellis JM, Pfaelzer C. Emergency pharmacotherapy: the evolving role of medications in the emergency department. In: Allen MH, editor. The growth and specialization of emergency psychiatry: new directions for mental health services. No. 67. San Francisco: Jossey-Bass Pub., Sept 1995
60. Bradwejn J, Shriqui C, Koszycki D, et al. Double-blind comparison of the effects of clonazepam and lorazepam in acute mania. J Clin Psychopharmacol 1990; 10: 403-8
61. Wetzel H, Benkert O. Lorazepam for the treatment of catatonic symptoms and severe psychomotor retardation. Am J Psychiatry 1988; 145: 1175-6
62. Ward ME, Saklad SR, Ereshefsky L. Lorazepam for the treatment of psychotic agitation. Am J Psychiatry 1986; 143: 1195-6
63. Extein I. Psychopharmacology in psychiatric emergencies. Int J Psychiatry Med 1980; 10: 189-204
64. Lerner Y, Lwow E, Levitan A, et al. Acute high-dose parenteral haloperidol treatment of psychosis. Am J Psychiatry 1979; 136: 1061-4
65. Chouinard G, Annable L, Turnier L, et al. A double-blind randomized clinical trial of rapid tranquilization with IM clonazepam and IM haloperidol in agitated psychotic patients with manic symptoms. Can J Psychiatry 1993; 38 Suppl. 4: 114-21
66. Martenyi F, Harangozo J, Mod L. Clonazepam for the treatment of stupor in catatonic schizophrenia [letter]. Am J Psychiatry 1989; 146: 1230
67. Mendoza R, Djenderedjian AH, Adams J, et al. Midazolam in acute psychotic patients with hyperarousal. J Clin Psychiatry 1987; 48: 291-2
68. Bond WS, Mandos LA, Kurtz MD. Midazolam for aggressivity and violence in three mentally retarded patients. Am J Psychiatry 1989; 146: 925-6
69. Busch FN, Miller FT, Weiden PJ. A comparison of two adjunctive treatment strategies in acute mama. J Clin Psychiatry 1989; 50: 453-5
70. Yassa R, Iskandar H, Lalinec M. Lorazepam as an adjunct in the treatment of catatonic states: an open clinical trial. J Clin Psychopharmacol 1990; 10: 66-8
71. Greenblatt DJ, Raskin A. Benzodiazepines: new indications. Psychopharmacol Bull 1986; 22: 77-8
72. Cohen S, Khan A. Respiratory distress with use of lorazepam in mania. J Clin Psychopahramcol 1987; 7: 199-200
73. Guirguis EF. Management of disturbed patients: an alternative to the use of mechanical restraints. J Clin Psychiatry 1978; 39: 295-303
74. Fink M, Sackeim HA. Convulsive therapy for schizophrenia? Schizophr Bull 1996; 22: 27-39
75. Kendell RE. The present status of electroconvulsive therapy. Br J Psychiatry 1981; 28: 661-3
76. Kellner CH. Is ECT the treatment of choice for first-break psychosis? Convulsive Ther 1995; 11: 155-7
77. Perera KM, Ferraro A, Pinto MR. Catatonia LSD-induced? Aust NZ J Psychiatry 1995; 29: 324-7
78. Jeffries JJ, Rakoff VM. ECT as a form of restraint. Can J Psychiatry 1983; 28: 661-3